Australian prescribers' perspectives on ART initiation in the era of “treatment as prevention”.
Saved in:
| Title: | Australian prescribers' perspectives on ART initiation in the era of “treatment as prevention”. |
|---|---|
| Authors: | Mao, Limin (AUTHOR), de Wit, John (AUTHOR), Adam, Philippe (AUTHOR), Post, Jeffrey J. (AUTHOR), Crooks, Levinia (AUTHOR), Kidd, Michael R. (AUTHOR), Slavin, Sean (AUTHOR), Kippax, Susan (AUTHOR), Wright, Edwina (AUTHOR) |
| Source: | AIDS Care. Nov2013, Vol. 25 Issue 11, p1375-1379. 5p. |
| Subjects: | Antiviral agents, Attitude (Psychology), Biomarkers, HIV infections, Internet, Medical personnel, Questionnaires, Research funding, Surveys, Professional practice, Descriptive statistics, CD4 lymphocyte count |
| Geographic Terms: | Australia |
| Abstract: | This study explores Australian prescribers' attitudes towards Treatment as Prevention (TasP) and their practices around initiating combination antiretroviral treatment (cART) for HIV. A brief online survey was conducted nationally amongst antiretroviral treatment (ART) prescribers in Australia. The sample broadly represented ART prescribers in Australia (N= 108), with 40.7% general practitioners (GPs), 25.9% sexual health clinic-based physicians and 21.3% hospital-based infectious diseases physicians. About 60% of respondents had been treating HIV-positive patients for more than 10 years. Respondents estimated that about 70–80% of all their HIV-positive patients were receiving ART. Over half of the prescribers agreed very strongly that their primary concern in recommending cART initiation was clinical benefit to individual patients rather than any population benefit. A majority of the prescribers (68.5%) strongly endorsed cART initiation before CD4+ T-cell count drops below 350 cells/mm3, and a further 22.2% strongly endorsed cART initiation before CD4+ T-cell count drops below 500 cells/mm3. Regarding the optimal timing of cART initiation, this study shows that prescribers in Australia in 2012 focus primarily on the benefits for their individual patients. Prescribers may need more convincing evidence of individual health benefits or increased knowledge about the population health benefits for a TasP approach to be effective in Australia. [ABSTRACT FROM PUBLISHER] |
| Copyright of AIDS Care is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | This study explores Australian prescribers' attitudes towards Treatment as Prevention (TasP) and their practices around initiating combination antiretroviral treatment (cART) for HIV. A brief online survey was conducted nationally amongst antiretroviral treatment (ART) prescribers in Australia. The sample broadly represented ART prescribers in Australia (N= 108), with 40.7% general practitioners (GPs), 25.9% sexual health clinic-based physicians and 21.3% hospital-based infectious diseases physicians. About 60% of respondents had been treating HIV-positive patients for more than 10 years. Respondents estimated that about 70–80% of all their HIV-positive patients were receiving ART. Over half of the prescribers agreed very strongly that their primary concern in recommending cART initiation was clinical benefit to individual patients rather than any population benefit. A majority of the prescribers (68.5%) strongly endorsed cART initiation before CD4+ T-cell count drops below 350 cells/mm3, and a further 22.2% strongly endorsed cART initiation before CD4+ T-cell count drops below 500 cells/mm3. Regarding the optimal timing of cART initiation, this study shows that prescribers in Australia in 2012 focus primarily on the benefits for their individual patients. Prescribers may need more convincing evidence of individual health benefits or increased knowledge about the population health benefits for a TasP approach to be effective in Australia. [ABSTRACT FROM PUBLISHER] |
|---|---|
| ISSN: | 09540121 |
| DOI: | 10.1080/09540121.2013.766304 |
